Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Raffles Medical Group (RAFLF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Raffles Medical Group $0.70, price $0.64, upside +10.0%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
RM
Broad data
Sep 24, 2026
Broad data
Sep 24, 2026
Raffles Medical Group
RAFLF · USNeutralQuality growthThe stock looks roughly fairly valued with average quality.
·Fair value $0.7040 · Fairly valued (+10.0%)
✓Quality 69/100
!Weak Growth (revenue 5y +6.1 %/yr)
!Thin margins · 9.2% net margin (TTM)
✓Low debt · generates free cash flow
✓4.7% dividend yield · Sustainable
!Narrow moat 40/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
60‑month range $0.4812 – $0.9971 · fair‑value band $0.5227 – $0.8747 · the $0.6400 price screens below the $0.7040 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.
Company profile
Raffles Medical Group Ltd provides private healthcare services in Singapore, Greater China, Vietnam, Cambodia, and Japan. It operates through four segments: Healthcare Services, Hospital Services, Investment Holdings, and Insurance Services.
Show more
Raffles Medical Group Ltd provides private healthcare services in Singapore, Greater China, Vietnam, Cambodia, and Japan. It operates through four segments: Healthcare Services, Hospital Services, Investment Holdings, and Insurance Services. The company operates Raffles Hospital that offers 24-hour acute and critical care; ambulance services and mobile medical calls to home, hotels, worksites, and onboard ships; and triage, emergency consultation, and inpatient ward admission services. Its hospital also provides various services, including covid 19 test, health screening, executive medical centre, statutory health check, dental, and chinese medicine; and specialist centers for cancer, children, counselling, diabetes and endocrine, dialysis, eye, fertility, heart, internal medicine, neuroscience, nuclear medicine, orthopaedic, pain management, rehabilitation, skin and aesthetics, surgery, urology, and woman, as well as ear, nose, and throat. In addition, the company offers health screening and clinical trial services; Raffles health eStore; and healthcare insurance to corporates and individuals. Further, it is involved in trading of pharmaceutical and nutraceutical products, and diagnostic equipment; operations of medical clinics and other general medical services; provision of management, consultancy, and third-party administration services; medical laboratory and imaging centre business; and investment property activities. The company was founded in 1976 and is based in Singapore.
Stock analysis
Raffles Medical Group (RAFLF) currently trades at $0.6400, while our model-based Fair Value estimate is $0.7040, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.7800 per share, and 14 of the 24 models we run sit above the $0.6400 price.
Bear case: the Earnings-Based group reads lowest at $0.2600, and 10 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $0.5227 (bear) to $0.8747 (bull), the price of $0.6400 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Raffles Medical Group reported revenue of 765M SGD in FY2025 versus 724M SGD in FY2021, a compound +1.4%/yr. Reported net income was 70.5M SGD in FY2025, compounding −4.3%/yr from FY2021.
Key figures
Market cap $1.5B · P/E ratio 21.3 · P/S ratio 1.97 · EPS (TTM) $0.0300 · Dividend yield 4.7% · Net margin 9.2% · Return on equity 6.7% · Return on assets (EBIT) 8.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 10%, RAFLF screens cheaper than that median.
Fair Value models
Bear $0.5227
Fair Value $0.7040
Bull $0.8747
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$0.5500
$0.7800
$1.09
81
Growth DCF
$0.5500
$0.7600
$1.04
79
Owner Earnings
$0.5900
$0.8300
$1.17
77
All 24 models by family
DCF Models
FCF DCF
$0.5500
$0.7800
$1.09
81
Owner Earnings
$0.5900
$0.8300
$1.17
77
5Y Revenue Exit
$0.5000
$0.7100
$0.9800
73
5Y EBITDA Exit
$0.6200
$0.9500
$1.34
75
5Y P/E Exit
$0.5700
$0.8400
$1.14
71
10Y Revenue Exit
$0.5100
$0.7000
$0.9600
67
10Y EBITDA Exit
$0.5900
$0.8500
$1.22
68
10Y P/E Exit
$0.5600
$0.7800
$1.08
64
Earnings-Based
Graham-Dodd
$0.2000
$0.7500
$1.01
64
Lynch FV
$0.1800
$0.2600
$0.3300
61
PEG = 1.0
$0.1800
$0.2600
$0.3300
57
EPV
$0.3600
$0.3900
$0.4200
74
Multiples
P/E Multiple
$0.4900
$0.6600
$0.8200
63
P/S Multiple
$0.3800
$0.5100
$0.6400
58
P/B Multiple
$0.3800
$0.5100
$0.6400
55
EV/EBIT
$0.6200
$0.7800
$0.9400
66
EV/EBITDA
$0.7300
$0.9300
$1.13
67
EV/Revenue
$0.4800
$0.6200
$0.7700
54
Asset-Based
NCAV (Graham)
$0.2200
$0.3000
$0.4500
54
Growth DCF
Growth DCF
$0.5500
$0.7600
$1.04
79
Rev-Margin DCF
$0.5000
$0.7100
$0.9700
73
Economic Profit
Residual Income
$0.3400
$0.3500
$0.3700
76
ROIC Compounder
$0.3600
$0.3900
$0.4200
72
Growth Earnings
Growth-Adj P/E
$0.3500
$0.4900
$0.6400
67
Notify me when RAFLF reaches fair value
Put RAFLF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
69/100
Of which business quality 69 · Market factors (momentum, volatility) 33
Profitability
34
Margins and returns on capital today
Quality Growth
42
Are margins and returns improving?
Cashflow
69
Earnings quality: real cash, not paper profit
Fin. Strength
94
Balance sheet, leverage, solvency risk
Investment
98
Disciplined investing over empire-building
Low Volatility
50
Calm price path (market factor)
Momentum
25
Price trend over the last 3–12 months (market factor)
52W Momentum
28
Distance to the 52-week high (market factor)
Net Issuance
85
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Start year 2020 (pandemic). Over 10 years: +6.4% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.2%
Dividend (yield on the price)4.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.2% vs −0.5%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 12%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in SGD, Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −0.3% a year for the price and +2.0% for the forecasts.
Forecast 2026 (sales)+4.1%
Forecast 2027 (sales)+4.5%
Projected 2028 (sales)+4.2%
Projected 2029 (sales)+3.9%
Projected 2030 (sales)+3.6%
Watch RAFLF, get fair value alerts →
Compare Raffles Medical Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $431.63 | $597.97 | +39% |
| Fresenius SE FRE | €43.64 | €34.49 | −21% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 225.00 SAR | 109.45 SAR | −51% |
| Tenet Healthcare Corporation THC | $257.93 | $274.35 | +6% |
| IHH Healthcare Berhad, an investment holding company, 5225 | 8.03 MYR | 4.87 MYR | −39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,889 | ₹2,908 | −67% |
| Encompass Health Corporation EHC | $123.47 | $94.47 | −23% |
| Fresenius Medical Care AG FMS | $22.27 | $45.84 | +106% |
| DaVita Inc DVA | $178.07 | $215.81 | +21% |
| Aier Eye Hospital Group 300015 | ¥7.91 | ¥10.86 | +37% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Raffles Medical Group (RAFLF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.7040 versus a price of $0.6400, about +10% upside (undervalued).
What is the fair value of RAFLF?
Our model-based fair value for Raffles Medical Group is $0.7040 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.6400.
What is the quality score of RAFLF?
Raffles Medical Group has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Raffles Medical Group (RAFLF)?
Our model-based price target is the fair value of $0.7040 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.5227, optimistic scenario $0.8747. It is a calculation from audited fundamentals, not an analyst target.
What is the Raffles Medical Group stock forecast for 2026?
Our models put fair value at $0.7040, about +10% upside versus a price of $0.6400 (undervalued). Cautious scenario $0.5227, optimistic scenario $0.8747. The calculation is refreshed regularly with new filings.
What is the revenue of Raffles Medical Group (RAFLF)?
Raffles Medical Group reported trailing-twelve-month revenue of about 766M SGD (latest available figure, as of Sep 24, 2026).
Does Raffles Medical Group pay a dividend?
Raffles Medical Group currently shows a dividend yield of about 4.69% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Raffles Medical Group (RAFLF)?
For today's price to be fair in a discounted-cash-flow model, Raffles Medical Group would have to grow free cash flow by +1.7 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of RAFLF use?
Our models discount Raffles Medical Group at 9.8 %: a base by market capitalisation (small), damped by beta 0.20, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Raffles Medical Group that is +1.7 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Raffles Medical Group (RAFLF) delivered so far?
Over the past 5 years revenue at Raffles Medical Group grew +6.1 % a year. The price currently implies +1.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Raffles Medical Group (RAFLF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Raffles Medical Group (+1.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Raffles Medical Group (RAFLF)?
The free-cash-flow yield on the price is 6.46 %: that much free cash flow Raffles Medical Group produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Raffles Medical Group (RAFLF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Raffles Medical Group it is $0.7040 per share (as of Sep 24, 2026), against a price of $0.6400. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Raffles Medical Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RAFLF trades below its calculated fair value: price $0.6400, fair value $0.7040, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RAFLF?
No. The price is what the market pays today ($0.6400); the fair value is what the company's own numbers justify ($0.7040). For Raffles Medical Group the two are $0.0640 per share apart. That gap is exactly why we show both numbers side by side.
How much is Raffles Medical Group worth?
The market values Raffles Medical Group at about $1.5B (market capitalisation, as of Sep 24, 2026). Per share that is $0.6400; our models calculate a fair value of $0.7040 per share.
What do the bullish and bearish scenarios say about RAFLF?
Our models span a range for Raffles Medical Group: cautious scenario $0.5227, base $0.7040, optimistic $0.8747 per share (as of Sep 24, 2026, price $0.6400). The range comes from different growth and margin assumptions, not from analyst opinions.
Which stocks are comparable to Raffles Medical Group?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Raffles Medical Group stock attractive at the current price?
The data as of Sep 24, 2026: price $0.6400, calculated fair value $0.7040 (+10%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RAFLF calculated?
We run Raffles Medical Group through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.7040, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Raffles Medical Group currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Raffles Medical Group (RAFLF)?
The closing price on Oct 2, 2026 was $0.6400. Our model-based fair value is $0.7040, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Raffles Medical Group right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Raffles Medical Group (RAFLF) come from?
Earnings per share at Raffles Medical Group grew +0.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.6 %, EBIT margin −4.4 %, tax rate −1.2 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Raffles Medical Group
How large is the market capitalisation of Raffles Medical Group (RAFLF)?
The market capitalisation of Raffles Medical Group is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Raffles Medical Group (RAFLF)?
The price-to-earnings ratio of Raffles Medical Group is 21.3. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Raffles Medical Group (RAFLF)?
The price-to-sales ratio of Raffles Medical Group is 1.97 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Raffles Medical Group (RAFLF)?
Earnings per share at Raffles Medical Group are $0.0300 (price ÷ EPS = P/E 21.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Raffles Medical Group (RAFLF)?
The dividend yield of Raffles Medical Group is 4.7% (payout 100%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Raffles Medical Group (RAFLF)?
The net margin of Raffles Medical Group is 9.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Raffles Medical Group (RAFLF)?
The return on equity (ROE) of Raffles Medical Group is 6.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Raffles Medical Group (RAFLF)?
On an EBIT basis the return on assets of Raffles Medical Group is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Raffles Medical Group (RAFLF)?
The operating margin of Raffles Medical Group is 11.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Raffles Medical Group (RAFLF)?
Revenue at Raffles Medical Group is growing +0.1% versus a year earlier (3y avg −2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Raffles Medical Group (RAFLF)?
Earnings per share at Raffles Medical Group are growing +22.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Raffles Medical Group (RAFLF) hold?
Raffles Medical Group holds more cash than debt, 223M SGD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.